HighLight Capital (HLC) is pleased to announce its recent participation in a secondary transaction involving ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, headquartered in Munich, Germany. This strategic investment underscores HLC’s commitment to identifying high-growth opportunities within the radiopharmaceutical space, ensuring portfolio diversity and strong returns.

In June 2024, ITM announced an equity investment of €188 million led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne.

ITM is built on extensive experience in the production and supply of high-quality medical radioisotopes for radiopharmaceutical therapy and diagnostics, supported by an established global supply network. Leveraging 20 years of pioneering expertise in radiopharmaceuticals, the company is advancing a comprehensive precision oncology pipeline, which includes two Phase III studies that combine its isotopes with a variety of targeting molecules.